Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19094370 | SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR | March 2025 | April 2025 | Allow | 1 | 0 | 0 | Yes | No |
| 19082485 | LINKED LIGATION | March 2025 | May 2025 | Allow | 2 | 0 | 0 | No | No |
| 19079070 | FORMULATIONS OF VIMSELTINIB | March 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19074158 | PLATELET DERIVATIVE COMPOSITIONS, AND PLURALITIES OF CONTAINERS CONTAINING SAME | March 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 19073932 | SPATIALLY ENCODED BIOLOGICAL ASSAYS | March 2025 | June 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19074001 | SPATIALLY ENCODED BIOLOGICAL ASSAYS | March 2025 | July 2025 | Allow | 4 | 0 | 0 | No | No |
| 19072385 | POLQ INHIBITORS | March 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19070930 | RAS INHIBITORS | March 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19070259 | METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTS | March 2025 | April 2025 | Allow | 2 | 1 | 0 | No | No |
| 19069098 | MACROCYCLIC DERIVATIVE AND USE THEREOF | March 2025 | June 2025 | Allow | 3 | 0 | 1 | No | No |
| 19066279 | EXOSOME SYSTEMS, PRODUCTS AND METHODS | February 2025 | April 2025 | Allow | 1 | 0 | 0 | No | No |
| 19065946 | MUSCLE TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING OF EXON 44 OF DYSTROPHIN IN A SUBJECT | February 2025 | May 2025 | Allow | 2 | 0 | 1 | Yes | No |
| 19063141 | NOVEL COMPOUNDS | February 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19062331 | RAS INHIBITORS | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19063190 | COMPOSITIONS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND METHODS FOR MAKING AND USING THE SAME | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19061465 | FORMULATIONS OF BENDAMUSTINE | February 2025 | May 2025 | Allow | 3 | 1 | 0 | No | No |
| 19061632 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | February 2025 | June 2025 | Allow | 4 | 0 | 0 | No | No |
| 19061509 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | February 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19061577 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | February 2025 | May 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19060293 | URSOLIC ACID MORPHOLINE SALT | February 2025 | June 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 19059018 | Zonal and Targeted Methods and Uses for Treating a Post-Traumatic Stress Disorder | February 2025 | June 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19058528 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19056056 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID MODIFICATIONS | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19054180 | GLP-1R AGONIST COMPOUND AND USE THEREOF | February 2025 | June 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19053424 | CULTURE MEDIUM AND METHOD FOR INDUCING IPSC DIFFERENTIATION TO OBTAIN MACROPHAGES AND USE THEREOF | February 2025 | May 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 19054630 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19054476 | Grape Plant Named 'Resilience' | February 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 19053808 | Mutated Glycoprotein of Vesicular Stomatitis Virus | February 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 19053784 | Mutated Glycoprotein of Vesicular Stomatitis Virus | February 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 19053925 | IN SITU COMBINATORIAL LABELING OF CELLULAR MOLECULES | February 2025 | June 2025 | Allow | 4 | 1 | 0 | No | No |
| 19052553 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | February 2025 | June 2025 | Allow | 4 | 1 | 0 | No | No |
| 19053277 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | February 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 19050547 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | February 2025 | June 2025 | Allow | 4 | 1 | 0 | No | No |
| 19048060 | MULTIOMIC ANALYSIS DEVICE AND METHODS OF USE THEREOF | February 2025 | May 2025 | Allow | 4 | 0 | 0 | No | No |
| 19046824 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING | February 2025 | May 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 19046435 | COMPOSITIONS AND METHODS FOR MINIMUM RISK PEST CONTROL | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19043567 | HUMANIZED ANTI-TISSUE FACTOR ANTIBODY, ANTIBODY-DRUG CONJUGATE PREPARED THEREFROM AND USE THEREOF | February 2025 | June 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19042986 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19042887 | GIP/GLP1 AGONIST COMPOSITIONS | January 2025 | May 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19042162 | Floribunda Rose Plant Named 'KORneukap' | January 2025 | April 2025 | Allow | 3 | 0 | 0 | No | No |
| 19040329 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | January 2025 | May 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 19039220 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | January 2025 | May 2025 | Allow | 3 | 1 | 0 | No | No |
| 19038538 | WRN INHIBITORS | January 2025 | April 2025 | Allow | 2 | 1 | 0 | No | No |
| 19038543 | WRN INHIBITORS | January 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19038532 | WRN INHIBITORS | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19036915 | ANTIBODIES THAT BIND TNFRSF25 | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19033679 | ANTIBODIES TARGETING IL3 | January 2025 | May 2025 | Allow | 4 | 1 | 1 | No | No |
| 19032739 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19032782 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19031698 | NICOTINAMIDE RIBOSIDE HYDROGEN MALATE CRYSTAL, AND ITS PREPARATION METHOD AND APPLICATION | January 2025 | April 2025 | Allow | 3 | 0 | 0 | No | No |
| 19030481 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | January 2025 | June 2025 | Abandon | 5 | 1 | 0 | No | No |
| 19027542 | METHODS AND KITS FOR LABELING CELLULAR MOLECULES | January 2025 | June 2025 | Allow | 5 | 1 | 1 | No | No |
| 19027603 | METHODS AND KITS FOR LABELING CELLULAR MOLECULES | January 2025 | June 2025 | Allow | 5 | 1 | 1 | No | No |
| 19029541 | METHODS OF DETECTING AND ENRICHING CIRCULATING TUMOR DNA | January 2025 | May 2025 | Allow | 4 | 1 | 0 | No | No |
| 19028631 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | January 2025 | May 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19025220 | GELS FOR INSULIN DELIVERY | January 2025 | April 2025 | Allow | 3 | 1 | 0 | No | No |
| 19025668 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | January 2025 | April 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 19024709 | USE OF REBOXETINE TO TREAT NARCOLEPSY | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19026296 | MRNA VACCINE ENCODING FUSION ANTIGEN AGAINST MPOX AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19025101 | CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 19023407 | ANTHRACENE-BASED COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF AS SOLAR THERMAL FUEL | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18995514 | Process For the Production of Methanol and Hydrogen from Methane Using a Solid Metal Hydroxide Reagent | January 2025 | June 2025 | Allow | 5 | 0 | 0 | No | No |
| 19022909 | SLEEP-IMPROVING COMPOSITIONS AND METHODS OF USE | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19022531 | LEVODOPA DOSING REGIMEN | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19021929 | LEVODOPA DOSING REGIMEN | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 19022122 | LEVODOPA DOSING REGIMEN | January 2025 | April 2025 | Allow | 3 | 1 | 0 | No | No |
| 19021696 | LEVODOPA DOSING REGIMEN | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 18831406 | Ficus Plant Named 'YAMKIMA' | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19020085 | INHIBITORS OF KIF18A AND USES THEREOF | January 2025 | June 2025 | Allow | 5 | 0 | 1 | No | No |
| 19020776 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19020628 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19019856 | GRAPEVINE PLANT NAMED 'BLOMG03' | January 2025 | April 2025 | Allow | 3 | 0 | 0 | No | No |
| 19018731 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19018788 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018805 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018817 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018754 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018773 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018178 | CATHARANTHUS PLANT NAMED 'SUNCATH 801' | January 2025 | March 2025 | Allow | 2 | 0 | 0 | No | No |
| 19018702 | ILOPROST COMPOSITIONS AND FORMULATIONS THEREOF | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19016827 | SUBSTITUTED QUINAZOLINES AS HDAC6 INHIBITORS | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19017356 | MUTANTS OF RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEINS | January 2025 | May 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19017364 | ANTI-MICROBIAL TREATMENT FOR SEEDS AND CROPS | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19015403 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19013003 | PHARMACEUTICAL SOLUTION OF AMLODIPINE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 19012978 | VIRAL VECTOR DELIVERY SYSTEM FOR BOTH RESPIRATORY AND DIGESTIVE TRACTS OF PIGS AND APPLICATION THEREOF | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19012840 | POLYSACCHARIDE COMPOUND WITH A DEFINED MOLECULAR STRUCTURE THAT CAN ELIMINATE THE TOXIC SIDE EFFECTS OF CHEMOTHERAPY DRUGS | January 2025 | June 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 19007236 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19007278 | COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION | December 2024 | April 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19007447 | METHODS OF TARGETED DELIVERY TO A HOST USING A CARRIER | December 2024 | May 2025 | Allow | 5 | 0 | 0 | No | No |
| 19005284 | DRUG POWDERIZATION WITHIN VIALS | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 19004850 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 19004480 | IMMUNOMODULATORY HYDROGEL AND PREPARATION METHOD THEREOF | December 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 19005540 | PREPARATION AND APPLICATION OF HIGH-ACTIVITY AND HIGH-SAFETY CARDAMINE VIOLIFOLIA SELENOPROTEIN STANDARD SAMPLE | December 2024 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 18879948 | NOVEL PHOSPHOENOLPYRUVATE CARBOXYLASE VARIANT AND METHOD FOR PRODUCING 5’-INOSINIC ACID USING SAME | December 2024 | June 2025 | Allow | 6 | 0 | 0 | Yes | No |
| 18879995 | NOVEL 5-DEHYDRO-2-DEOXYGLUCONOKINASE VARIANT AND METHOD FOR PRODUCING 5�-INOSINIC ACID USING SAME | December 2024 | May 2025 | Allow | 5 | 0 | 0 | No | No |
| 19006012 | CHRYSANTHEMUM PLANT NAMED 'G24MAG01VA' | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19004681 | Syringa Plant Named 'G13110' | December 2024 | April 2025 | Allow | 3 | 0 | 0 | No | No |
| 19004282 | ZANTEDESCHIA PLANT NAMED 'DO21PW104' | December 2024 | March 2025 | Allow | 3 | 0 | 0 | No | No |
| 19003381 | ORGANOSELENIUM BENZIMIDAZOLE COMPOUNDS FOR TREATING CANCER | December 2024 | March 2025 | Allow | 2 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for tech-center 1600.
With a 29.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Technology Center 1600 covers Biotechnology and Organic Chemistry. This technology center has examined 670,102 patent applications in our dataset, with an overall allowance rate of 61.0%. Applications typically reach final disposition in approximately 30 months.
Applications in Technology Center 1600 receive an average of 1.81 office actions before reaching final disposition. The median prosecution time is 30 months.
This technology center encompasses a broad range of technical subject matter. Prosecution strategies should be tailored based on the specific art unit and examiner assigned to your application. Review the group, art unit, and examiner-level statistics for more targeted strategic insights.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.